Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1271953 10.3389/fphar.2023.1271953 Pharmacology Correction Corrigendum: Induction of RIPK3/MLKL-mediated necroptosis by Erigeron breviscapus injection exhibits potent antitumor effect Guo et al. 10.3389/fphar.2023.1271953 Guo Xiuping 1 Li Rui 1 Cui Jinjin 1 Hu Chujuan 1 Yu Haoyang 1 Ren Ling 1 Cheng Yangyang 1 Jiang Jiandong 1 * Ding Xiao 2 * Wang Lulu 1 * 1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China 2 State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China

Edited and reviewed by: Zhaohui Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, China

 *Correspondence: Jiandong Jiang, jiang.jdong@163.com; Xiao Ding, dingxiao@mail.kib.ac.cn; Lulu Wang, wanglulu@imb.cams.cn 28 08 2023 2023 14 1271953 03 08 2023 14 08 2023 Copyright © 2023 Guo, Li, Cui, Hu, Yu, Ren, Cheng, Jiang, Ding and Wang. 2023 Guo, Li, Cui, Hu, Yu, Ren, Cheng, Jiang, Ding and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Induction of RIPK3/MLKL-mediated necroptosis by Erigeron breviscapus injection exhibits potent antitumor effect by Guo X, Li R, Cui J, Hu C, Yu H, Ren L, Cheng Y, Jiang J, Ding X and Wang L (2023). Front. Pharmacol. 14:1219362. doi: 10.3389/fphar.2023.1219362 Erigeron breviscapus injection Dengzhanxixin Erigeron breviscapus (Vant.) Hand.-Mazz colorectal cancer necroptosis drug resistance section-at-acceptance Experimental Pharmacology and Drug Discovery

In the published article, there was an error in Figure 2 as published. The upper panels in Figures 2B, D were inadvertently misused during the final assembly of Figure 2. The corrected Figure 2 appear below.

EBI suppresses growth, migration, and invasion of SW620 cells. (A) SW620 cells were observed for morphologic changes at 12 h after EBI (10, 15, 20, 40, and 100 μg/mL) treatment. Scale bars indicate 50 μm. (B, C) The representative image (B) and quantitative analysis (C) of migrated cells after exposure to EBI (10, 15, 20, and 40 μg/mL, 24 h). Scale bars indicate 50 μm. (D, E) The representative image (D) and quantitative analysis (E) of invaded cells after exposure to EBI (10, 15, 20, and 40 μg/mL, 24 h). Scale bars indicate 50 μm. Mean ± SEM. ***p < 0.001, ****p < 0.0001 vs. EBI 0 μg/mL group (one-way ANOVA).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.